Every Dose In Stock: Your Complete Treatment Journey
Wegovy vs Mounjaro Difference: Complete Dose Range Available
The fundamental difference between Wegovy and Mounjaro lies in their complete dose escalation pathways, both fully stocked at EverydayMeds. Wegovy follows a structured 5-dose journey: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. Each dose serves a specific purpose in gradually introducing your body to semaglutide while minimising side effects. Mounjaro follows its own tirzepatide escalation schedule with different dose increments and timing, reflecting its dual GIP and GLP-1 receptor mechanism.
Having every dose available means patients never face treatment interruption due to supply issues or pharmacy switching. This continuity is crucial during the critical first 16 weeks when your body adapts to each new dose level. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which treatment pathway suits your individual needs and medical history.
Pricing Structure: Wegovy and Mounjaro Difference Across All Doses
Understanding the cost difference between Wegovy and Mounjaro requires examining each dose level individually. Wegovy pricing at EverydayMeds starts with 0.25mg at £79.99, progressing to 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our Getting Started bundles provide convenience: the Intro Duo (0.25mg & 0.5mg) costs £169.99, while the Progress Trio (0.5mg, 1mg & 1.7mg) is £369.99. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these prices.
The pricing difference between Wegovy and Mounjaro reflects their distinct manufacturing processes and dual-hormone mechanisms. Both treatments require the same rigorous cold-chain storage and next-day delivery, included in every order. Our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, ensuring long-term treatment continuity once you reach your target dose.
Clinical Evidence: Understanding Wegovy vs Mounjaro Treatment Outcomes
The clinical evidence difference between Wegovy and Mounjaro comes from separate trial programmes with distinct study designs. In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent results across different patient populations, including those with type 2 diabetes.
Mounjaro's clinical programme evaluated tirzepatide's dual GIP and GLP-1 receptor approach in separate studies with different methodologies. Both treatments demonstrated cardiovascular benefits in their respective trials, though direct comparison requires careful interpretation due to varying study protocols and patient populations. Your prescriber can discuss which clinical evidence profile aligns best with your health goals.
How Wegovy Works: Mechanism Behind the Treatment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones. This prescription-only medicine works by binding to GLP-1 receptors in your brain's appetite control centres, reducing hunger signals and promoting satiety after smaller meals. The once-weekly injection gradually slows gastric emptying, helping you feel fuller for longer periods. Semaglutide may also reduce food cravings and the reward response to high-calorie foods, supporting behavioural changes alongside a reduced-calorie diet and increased physical activity. This mechanism explains why dose escalation is essential—your body needs time to adapt to increasing semaglutide levels while minimising gastrointestinal side effects.
Complete Ordering Process: From Assessment to All Doses
Accessing every Wegovy dose through EverydayMeds begins with our 3-minute online clinical assessment, designed to capture your medical history, current medications, and weight management goals. Our UK-registered prescribers (GPhC #9012878) review your assessment within 3 working days, or 24 hours with express service, ensuring appropriate dose selection and treatment suitability. Once approved, your Wegovy dose ships via next-day cold-chain delivery, maintaining the critical 2-8°C temperature throughout transit. This streamlined process applies to every dose level, from initial 0.25mg through to 2.4mg maintenance, ensuring consistent access without pharmacy switching. Our clinical team monitors your progression and can adjust dosing recommendations based on your individual response and tolerability.
Storage and Practical Considerations: Key Wegovy vs Mounjaro Differences
A significant practical difference between Wegovy and Mounjaro lies in storage flexibility once removed from refrigeration. Wegovy can remain at room temperature (below 30°C) for up to 6 weeks, compared to Mounjaro's 21-day limit, offering superior travel and lifestyle flexibility. Both treatments arrive in pre-filled FlexTouch pens requiring refrigerated storage at 2-8°C before first use, with next-day cold-chain delivery maintaining temperature integrity. The dose escalation schedules differ: Wegovy's 4-week intervals between doses versus Mounjaro's varying escalation timeline, reflecting their distinct mechanisms and tolerance profiles. Each pen delivers precise dosing through the FlexTouch system, with dose counters ensuring accurate administration. This storage advantage makes Wegovy particularly suitable for patients with active lifestyles or frequent travel commitments.
Complete Journey Planning: Why All Doses Matter for Wegovy vs Mounjaro
The difference between successful Wegovy and Mounjaro treatment lies in consistent dose progression without interruption. Having access to every dose prevents the common problem of treatment discontinuation due to supply shortages at individual dose levels. Many patients experience their best results during the transition from 1.7mg to 2.4mg maintenance, making this dose availability critical for long-term success.
Our complete inventory means patients can plan their entire 17+ week journey from starter dose to maintenance without uncertainty. This planning advantage eliminates the stress of sourcing individual doses from multiple pharmacies, each with different clinical assessment requirements and varying stock levels. Both Wegovy and Mounjaro benefit from this comprehensive approach, though their different escalation timelines require distinct inventory management expertise.
Expert Support: Making the Right Choice Between Treatments
Choosing between Wegovy and Mounjaro requires expert clinical guidance considering your individual medical history, lifestyle factors, and treatment preferences. Our UK-registered clinical team (GPhC #9012878) evaluates factors including existing medical conditions, current medications, previous weight management attempts, and practical considerations like storage requirements. The consultation process includes discussing expected timelines, potential side effects, and long-term maintenance planning for whichever treatment pathway suits you best. We provide ongoing support throughout your dose escalation journey, with clinical reviews available as you progress through each strength. This comprehensive support ensures you receive optimal treatment outcomes whether you choose Wegovy's GLP-1 approach or Mounjaro's dual-hormone mechanism, with every dose readily available for seamless treatment continuation. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and access our complete range of prescription-only weight management treatments.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
